LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.14

Massimo

31.18

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.542 51.415
EPS	0.68
Margine di Profitto	42.663
Dipendenti	182
EBITDA	-7.8M 73M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+6.29% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	271M 3.8B
Apertura precedente	31.15
Chiusura precedente	31.15

Notizie sul Sentiment di mercato

By Acuity

37%

63%

118 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2026, 22:54 UTC

Utili

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 mag 2026, 23:17 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mag 2026, 23:16 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mag 2026, 23:15 UTC

Utili

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mag 2026, 23:14 UTC

Utili

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mag 2026, 23:02 UTC

Discorsi di Mercato

Utili

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mag 2026, 22:59 UTC

Discorsi di Mercato

Utili

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mag 2026, 22:24 UTC

Utili

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Revenue Growth 47%>XRO.AU

13 mag 2026, 22:22 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mag 2026, 22:18 UTC

Utili

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mag 2026, 22:16 UTC

Utili

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mag 2026, 22:13 UTC

Utili

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mag 2026, 22:12 UTC

Utili

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mag 2026, 22:09 UTC

Utili

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mag 2026, 22:00 UTC

Utili

Cisco to Shed Jobs for All-In AI Push -- Update

13 mag 2026, 21:11 UTC

Utili

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.29% in crescita

Previsioni per 12 mesi

Media 33.1 USD 6.29%

Alto 35 USD

Basso 31.5 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

118 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.